Q2 2025 Exelixis Inc Earnings Call Transcript
Key Points
- Exelixis Inc (EXEL) reported strong second-quarter 2025 financial results with total revenues of approximately $568 million, driven by the cabozantinib franchise.
- The cabozantinib US business showed robust growth, with revenues increasing 19% year over year to $520 million.
- The launch of CABOMETYX in neuroendocrine tumors (NETs) is off to a strong start, quickly capturing a 35% new patient share in the oral therapies segment.
- Positive topline results from the STELLAR-303 trial in colorectal cancer, demonstrating a statistically significant improvement in overall survival.
- Exelixis Inc (EXEL) maintains a strong balance sheet with approximately $1.4 billion in cash and marketable securities, allowing for continued R&D investment and share repurchases.
- The decision not to advance the STELLAR-305 trial in head and neck cancer into Phase 3 due to competitive landscape and commercial opportunity concerns.
- Higher gross-to-net deductions in the second quarter of 2025, primarily related to increased 340B volume, impacting overall profitability.
- Clinical trial sales were significantly lower in the second quarter compared to the first quarter of 2025, indicating potential volatility in this revenue stream.
- The competitive landscape in oncology remains challenging, with Exelixis Inc (EXEL) needing to make tough capital allocation decisions.
- The regulatory environment is described as highly dynamic, necessitating a conservative approach to data interpretation and communication.
Good day, ladies and gentlemen, and welcome to the Exelixis second-quarter 2025 financial results conference call. My name is [Towanda] and I'll be your operator for today. As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to your host for today, Miss Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations. Please proceed.
Thank you, Towanda, and thank you, all, for joining us for the Exelixis second-quarter 2025 financial results conference call. Joining me on today's call are Mike Morrissey, our President and CEO; Chris Senner, our Chief Financial Officer; PJ Haley, our Executive Vice President of Commercial; Amy Peterson, our Chief Medical Officer; and Dana Aftab, our Chief Scientific Officer, who will review our progress for the second-quarter 2025 and the June 30, 2025.
During the call today, we will refer to financial members -- measures not calculated according to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
